BG104245A - Фармацевтични състави, съдържащи плазмен протеин - Google Patents

Фармацевтични състави, съдържащи плазмен протеин

Info

Publication number
BG104245A
BG104245A BG104245A BG10424500A BG104245A BG 104245 A BG104245 A BG 104245A BG 104245 A BG104245 A BG 104245A BG 10424500 A BG10424500 A BG 10424500A BG 104245 A BG104245 A BG 104245A
Authority
BG
Bulgaria
Prior art keywords
plasma protein
pharmaceutical compositions
containing pharmaceutical
fraction
relates
Prior art date
Application number
BG104245A
Other languages
English (en)
Other versions
BG64749B1 (bg
Inventor
Lajos Hegedues
Krisztina Krempels
Krisztina Paal
Gabor Pethoe
Original Assignee
Human Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Rt. filed Critical Human Rt.
Publication of BG104245A publication Critical patent/BG104245A/bg
Publication of BG64749B1 publication Critical patent/BG64749B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретението се отнася до водоразтворими продукти и фармацевтични състави в течно и твърдо състояние, главно за парентерална употреба. Те се състоятот терапевтично активно вещество (с ниска разтворимост във вода, имащо значителен афинитет на свързване с плазмен протеин) и фракция плазмен протеин в контролирано състояние за агрегиране. Активното вещество и фракцията плазмен протеин са свързани чрез нековалентни връзки. Изобретението се отнася идо методи за получаване на продуктите и фармацевтичните състави.
BG104245A 1997-09-18 2000-03-16 Фармацевтични състави, съдържащи плазмен протеин BG64749B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9701554A HUP9701554D0 (en) 1997-09-18 1997-09-18 Pharmaceutical composition containing plazma proteins

Publications (2)

Publication Number Publication Date
BG104245A true BG104245A (bg) 2000-11-30
BG64749B1 BG64749B1 (bg) 2006-02-28

Family

ID=90014222

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104245A BG64749B1 (bg) 1997-09-18 2000-03-16 Фармацевтични състави, съдържащи плазмен протеин

Country Status (33)

Country Link
US (5) US6743826B1 (bg)
EP (1) EP0981375B1 (bg)
JP (1) JP2001508806A (bg)
KR (1) KR100587962B1 (bg)
CN (1) CN1189216C (bg)
AR (1) AR017120A1 (bg)
AT (1) ATE230611T1 (bg)
AU (1) AU734695B2 (bg)
BG (1) BG64749B1 (bg)
BR (1) BR9812469A (bg)
CA (1) CA2269923C (bg)
CZ (1) CZ301326B6 (bg)
DE (1) DE69810612T2 (bg)
DK (1) DK0981375T3 (bg)
EA (1) EA004700B1 (bg)
ES (1) ES2187062T3 (bg)
HR (1) HRP980499A2 (bg)
HU (1) HUP9701554D0 (bg)
IL (1) IL135055A (bg)
LT (1) LT4736B (bg)
LV (1) LV12493B (bg)
NO (1) NO325294B1 (bg)
NZ (1) NZ503302A (bg)
PL (1) PL193067B1 (bg)
PT (1) PT981375E (bg)
RO (1) RO118695B1 (bg)
RS (1) RS50102B (bg)
SI (1) SI20189B (bg)
SK (1) SK284683B6 (bg)
TR (1) TR200001545T2 (bg)
TW (1) TWI222365B (bg)
WO (1) WO1999013914A1 (bg)
ZA (1) ZA988585B (bg)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US8137684B2 (en) * 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
WO2000047187A1 (en) * 1999-02-11 2000-08-17 Kinetana Inc. Serum albumin-based parenteral formulations of polyene macrolides
IL148234A0 (en) 1999-09-16 2002-09-12 Novo Nordisk As Composition for ivf
AU2001253336A1 (en) * 2000-04-10 2001-10-23 Teva Pharmaceutical Industries Ltd. Method 0f administration of paclitaxel-plasma protein formulation
IL152180A0 (en) * 2000-04-10 2003-05-29 Teva Pharma Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
CA2445763A1 (en) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
GR1004274B (el) 2002-07-16 2003-06-23 Medexis ���� Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
CA2492297A1 (en) 2002-07-16 2004-01-22 Medexis S.A. Steroid conjugates, preparation thereof and the use thereof
AU2003262025A1 (en) * 2002-09-12 2004-04-30 Nihon Medi-Physics Co., Ltd. Preparation for controlling binging of drug to plasma protein
KR20200083657A (ko) 2002-12-09 2020-07-08 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
WO2004101620A2 (en) * 2003-05-01 2004-11-25 Compound Therapeutics, Inc. Serum albumin scaffold-based proteins and uses thereof
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
EP1807146A4 (en) * 2004-09-29 2013-07-03 Tel Hashomer Medical Res Infrastructure & Services Ltd COMPOSITION FOR IMPROVING THE EFFICACY OF DRUG DELIVERY
US20060198891A1 (en) * 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
EP2066309B1 (en) 2007-04-04 2012-08-29 Sigmoid Pharma Limited An oral pharmaceutical composition
EP2061587A1 (en) 2007-04-26 2009-05-27 Sigmoid Pharma Limited Manufacture of multiple minicapsules
WO2009116557A1 (ja) * 2008-03-21 2009-09-24 富士フイルム株式会社 薬剤含有組成物
CN101658516B (zh) * 2008-08-26 2011-10-05 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
CA2762179A1 (en) 2009-05-18 2010-11-25 Sigmoid Pharma Limited Composition comprising oil drops
CN107582526A (zh) 2009-08-12 2018-01-16 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
EP2480208A1 (en) 2009-09-23 2012-08-01 Indu Javeri Methods for the preparation of liposomes
US9629920B2 (en) 2009-12-18 2017-04-25 Exodos Life Sciences Limited Partnership Methods and compositions for stable liquid drug formulations
WO2011097149A2 (en) * 2010-02-03 2011-08-11 Oncbiomune, L.L.C. Taxane-and taxoid-protein compositions
AR093275A1 (es) 2010-03-17 2015-05-27 Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
AU2015232994B2 (en) 2014-03-18 2020-05-28 Izun Pharmaceuticals Corp. Protein-bound cannabinoid compositions
AU2015341695B2 (en) 2014-11-07 2021-07-08 Sublimity Therapeutics Limited Compositions comprising cyclosporin
AR100034A1 (es) 2015-01-30 2016-09-07 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas
EP3294900B1 (en) * 2015-05-08 2021-09-22 Spectral Platforms, Inc. Use of albumin-based non-covalent complexes for the detection of micro-organisms
CN112807299B (zh) 2015-05-15 2022-06-24 珠海贝海生物技术有限公司 包含多西他赛和人血清白蛋白的固体组合物及其制备方法和应用
EP3310338A4 (en) * 2015-06-18 2018-12-26 Matinas BioPharma Nanotechnologies, Inc. Compositions and methods for treating inflammatory disease or conditions
WO2017083397A1 (en) * 2015-11-09 2017-05-18 Cayo Max A Cardiac glycosides for the treatment of hypercholesterolemia
WO2018027029A1 (en) * 2016-08-03 2018-02-08 Zhuhai Beihai Biotech Co., Ltd. Formulations of fosaprepitant and aprepitant
CN110062622B (zh) 2016-10-27 2022-10-14 珠海贝海生物技术有限公司 多西他赛和人血清白蛋白的中性pH组合物
RU2019131436A (ru) 2017-03-09 2021-04-10 Изун Фармасьютикалс Корп. Стабилизированные композиции связанных с белком каннабиоидов
US11105747B2 (en) 2017-03-20 2021-08-31 Spectral Platforms, Inc. Spectroscopic methods to detect and characterize microorganisms
MX2020000265A (es) 2017-07-07 2020-07-22 Epicentrx Inc Composiciones para la administración parenteral de agentes terapéuticos.
AU2019232153B2 (en) * 2018-03-09 2023-07-13 Panoptes Pharma Ges.M.B.H. Ophthalmic formulation
EP3811982A1 (en) * 2019-10-25 2021-04-28 Université de Strasbourg Protein-based biomaterial with viscoelastic behaviour, process for obtaining it and uses thereof
CN111529506B (zh) * 2020-05-18 2021-09-03 同济大学 一种两性霉素b白蛋白纳米制剂及其制备方法和应用
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
KR102435211B1 (ko) * 2021-06-29 2022-08-23 (주)진셀바이오텍 알부민을 고효율로 생산하는 식물 세포주 및 이의 용도
CN114544926A (zh) * 2021-12-02 2022-05-27 浙江鑫科医疗科技有限公司 一种血清蛋白稳定剂
CN115236216B (zh) * 2022-06-07 2024-03-01 合肥和合医疗科技有限公司 高效液相色谱串联质谱检测全血中免疫抑制剂的试剂盒，其制备方法和检测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4833013A (bg) * 1971-08-30 1973-05-07
DE2653534C2 (de) * 1975-12-22 1986-08-28 Baxter Travenol Laboratories, Inc., Deerfield, Ill. Feste Antihämophilen-Faktor-Präparation und Verfahren zu ihrer Herstellung
JPS58216126A (ja) * 1982-06-11 1983-12-15 Ono Pharmaceut Co Ltd 可容化製剤
DE3702105A1 (de) * 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
JPS63215640A (ja) * 1987-03-04 1988-09-08 Nippon Hai Potsukusu:Kk 易吸収性抗炎症剤及びその製造方法
EP0326618A1 (en) * 1987-03-04 1989-08-09 Nippon Hypox Laboratories Incorporated Medicinal composition containing albumin as carrier and process for its preparation
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5356927A (en) * 1992-12-02 1994-10-18 Thomas Jefferson University Methods of treating plasmodium and babesia parasitic infections
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9510716D0 (en) * 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
TR199600775A2 (tr) 1996-09-27 1997-09-21 Tureks Turunc Madencilik Ic Ve Taslara eskitilmis görüntü kazandirilmasi icin bir yöntem.
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Also Published As

Publication number Publication date
SI20189A (sl) 2000-10-31
HUP9701554D0 (en) 1997-11-28
CA2269923C (en) 2003-07-22
US20070232536A1 (en) 2007-10-04
TWI222365B (en) 2004-10-21
AR017120A1 (es) 2001-08-22
DK0981375T3 (da) 2003-05-05
US6743826B1 (en) 2004-06-01
HRP980499A2 (en) 1999-12-31
SK3292000A3 (en) 2000-08-14
US7119124B2 (en) 2006-10-10
EP0981375A1 (en) 2000-03-01
DE69810612D1 (de) 2003-02-13
WO1999013914A1 (en) 1999-03-25
CN1189216C (zh) 2005-02-16
CZ2000952A3 (cs) 2000-09-13
CA2269923A1 (en) 1999-03-25
BR9812469A (pt) 2002-02-05
LV12493B (en) 2001-01-20
SK284683B6 (sk) 2005-09-08
RO118695B1 (ro) 2003-09-30
LT2000018A (en) 2000-08-25
PT981375E (pt) 2003-04-30
CZ301326B6 (cs) 2010-01-20
PL193067B1 (pl) 2007-01-31
CN1270529A (zh) 2000-10-18
ATE230611T1 (de) 2003-01-15
KR100587962B1 (ko) 2006-06-13
NO20001371D0 (no) 2000-03-16
LT4736B (lt) 2000-12-27
IL135055A (en) 2004-09-27
RS50102B (sr) 2009-01-22
PL339369A1 (en) 2000-12-18
AU9362398A (en) 1999-04-05
AU734695B2 (en) 2001-06-21
US20100076008A1 (en) 2010-03-25
US20040014655A1 (en) 2004-01-22
BG64749B1 (bg) 2006-02-28
NZ503302A (en) 2001-08-31
JP2001508806A (ja) 2001-07-03
ES2187062T3 (es) 2003-05-16
LV12493A (en) 2000-06-20
EP0981375B1 (en) 2003-01-08
NO325294B1 (no) 2008-03-17
EA004700B1 (ru) 2004-06-24
IL135055A0 (en) 2001-05-20
KR20010052072A (ko) 2001-06-25
DE69810612T2 (de) 2003-10-02
SI20189B (sl) 2007-10-31
US20050064028A1 (en) 2005-03-24
EA200000331A1 (ru) 2000-10-30
NO20001371L (no) 2000-05-18
US7501455B2 (en) 2009-03-10
TR200001545T2 (tr) 2000-10-23
US8946167B2 (en) 2015-02-03
YU16600A (sh) 2003-08-29
ZA988585B (en) 2000-03-13

Similar Documents

Publication Publication Date Title
BG104245A (bg) Фармацевтични състави, съдържащи плазмен протеин
WO1998007745A3 (en) Compositions and methods for treating infections using analogues of indolicidin
EP1746160A3 (en) Hepatocyte growth factor receptor antagonists and uses thereof
AU6604798A (en) Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
EE03923B1 (et) S-omeprasool neutraalsel kujul, selle valmistamise protsess ja seda sisaldavad ravimsegud
IL129762A0 (en) Novel macromolecules methods for their preparation pharmaceutical compositions thereof and their use as anti-influenza agents
HUP0002381A3 (en) Apolipoprotein a-1 agonist peptide derivatives, complexes thereof and pharmaceutical compositions comprising their
EP1175909A3 (en) Therapeutic methods and compositions based on serrate proteins and nucleic acids
HUP0000383A3 (en) Tetrahydrochinoxalinyl-aminoalkane phosphonic acids, process for their preparation and pharmaceutical compositions thereof
AU1887999A (en) Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
AU3262497A (en) Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
ZA945656B (en) 1-Benzenesfulfonyl-1,3-dihydro-indol-2-one derivatives their preparation and pharmaceutical compositions in which they are present
HUP0001555A3 (en) Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
AU4871797A (en) Magnesium (-)hydroxycitrate, preparation process, uses and compositions, in particular pharmaceutical compositions, containing it
HUP0000426A3 (en) Novel benzonaphthyridines, pharmaceutical compositions and use thereof and process for their preparation
HUP0002404A3 (en) Amino acid derivatives, pharmaceutical compositions comprising thereof, process for preparation them and their use
CA2255539A1 (en) Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
WO2000042031A3 (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
IL125081A0 (en) Ob protein receptor and related compositions and methods
HUP9900987A3 (en) Camptothecin derivatives process for their preparation, use thereof as antitumor agents and pharmaceutical compositions containing them
CA2337667A1 (en) Dextran-leptin conjugates, pharmaceutical compositions and related methods
AU7216498A (en) Inhibitors of the urokinase receptor
AU5069298A (en) Novel triterpene glycoside compound, process for preparation thereof and anti-cancer composition containing the same
AU8031598A (en) 3-aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them
EP0784981A3 (en) Obesity protein formulations